文献速递银屑病与炎症性皮肤病

简化银屑病指数评估司库奇尤单抗对中重度银屑病严重程度及心理社会影响的效果:IPSI-PSO研究

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-10-02

IPSI-PSO研究在法国17个中心纳入120例中重度斑块状银屑病患者,开放标签接受司库奇尤单抗300mg治疗至48周。医生评分SPI严重程度(proSPI-s)与PASI高度相关,患者自评(saSPI-s)与PASI相关性稍弱,心理社会影响评分(SPI-p)与DLQI变化一致至52周。SPI可作为患者自评工具,支持远程评估。

要点

  • 司库奇尤单抗治疗16周时proSPI-s、saSPI-s和PASI均大幅下降,并维持至52周
  • proSPI-s与PASI高度相关,支持其用于评估治疗反应
  • SPI-p可评估心理社会影响,SPI支持患者自评及远程评估

核心结论

  • 司库奇尤单抗降低PASI与proSPI-s高度相关,支持proSPI-s评估治疗反应。
  • 患者自评saSPI-s与PASI相关性稍弱,但患者能独立完成有效评估。
  • SPI包含心理社会影响评估(SPI-p),可作为患者自评工具并支持远程评估。

研究设计与样本

  • 开放标签、多中心研究,涉及17个法国中心。
  • 中重度斑块状银屑病患者接受司库奇尤单抗300mg皮下注射,基线至W4每周一次,之后每4周一次至W48。
  • 共纳入120例患者(69.2%男性;平均年龄45.9岁;平均银屑病病程21.6年)。

主要发现

  • 基线平均评分:proSPI-s 24.9,saSPI-s 23.5,PASI 23.1,SPI-p 8.2,DLQI 13.6。
  • 16周时严重程度评分:proSPI-s 2.3,saSPI-s 2.2,PASI 2.2,并维持至W52。
  • 心理社会影响评分下降维持至W52:SPI-p和DLQI在W16分别为2.1和1.5,在W52分别为1.5和1.9。

临床怎么用

  • 临床可用proSPI-s替代PASI评估司库奇尤单抗治疗反应。
  • SPI支持患者自评银屑病严重程度及心理社会影响,必要时可远程完成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The utility of the Simplified Psoriasis Index (SPI), a recently developed multidomain tool for assessing psoriasis, was investigated in a study assessing response to secukinumab. METHODS: In an open-label, multicentre study involving 17 French centres, patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously once weekly from baseline to W4, then every 4 weeks until W48. Dermatologist-scored SPI psoriasis severity (proSPI-s) was compared with Psoriasis Area and Severity Index (PASI). Patient self-assessed severity (saSPI-s) and psychosocial impact (SPI-p) were compared with PASI and Dermatology Life Quality Index (DLQI), respectively. RESULTS: We included 120 patients (69.2% male; mean age 45.9 years; mean duration of psoriasis 21.6 years). Mean baseline scores were as follows: proSPI-s 24.9, saSPI-s 23.5, PASI 23.1, SPI-p 8.2 and DLQI 13.6. Severity scores achieved by 16 weeks (proSPI-s 2.3, saSPI-s 2.2 and PASI 2.2) were maintained to W52. Reductions in mean psychosocial impact scores were maintained to W52 (SPI-p and DLQI, respectively, 2.1 and 1.5 at W16; 1.5 and 1.9 at W52). CONCLUSIONS: Decrease of PASI scores in response to secukinumab was closely correlated with proSPI-s, supporting the latter's suitability for assessing response to therapy. Although the correlation between PASI and saSPI-s was slightly weaker, patients were able to complete a valid assessment of their psoriasis independently, and thus potentially remotely. With the added benefit of psychosocial impact assessment (SPI-p), SPI provides a valid tool enabling patients to assess their own psoriasis, remotely if necessary.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Richard MA, Lacour JP, Konstantinou MP, et al. Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study. J Eur Acad Dermatol Venereol. 2020. PMID: 32815591. doi:10.1111/jdv.16893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。